Chia Nan University of Pharmacy & Science Institutional Repository:Item 310902800/34402
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18270/20497 (89%)
Visitors : 12389182      Online Users : 764
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34402


    題名: Lysophosphatidic Acid Receptor Antagonists and Cancer: The Current Trends, Clinical Implications, and Trials
    作者: Lin, Yu-Hsuan
    Lin, Yueh-Chien
    Chen, Chien-Chin
    貢獻者: Natl Sun Yat Sen Univ, Inst Biomed Sci
    Kaohsiung Vet Gen Hosp, Dept Otolaryngol Head & Neck Surg
    Natl Yang Ming Chiao Tung Univ, Sch Med
    Chung Shan Med Univ, Sch Med
    Natl Taiwan Univ, Dept Life Sci
    Harvard Med Sch, Boston Childrens Hosp, Dept Surg, Vasc Biol Program
    Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pathol
    Chia Nan Univ Pharm & Sci, Dept Cosmet Sci
    關鍵詞: antagonist
    cancer
    clinical trial
    lysophosphatidic acid
    lysophosphatidic receptor
    therapy
    日期: 2021
    上傳時間: 2023-11-11 11:49:53 (UTC+8)
    出版者: MDPI
    摘要: Lysophosphatidic acid (LPA) is a bioactive lipid mediator primarily derived from membrane phospholipids. LPA initiates cellular effects upon binding to a family of G protein-coupled receptors, termed LPA receptors (LPAR1 to LPAR6). LPA signaling drives cell migration and proliferation, cytokine production, thrombosis, fibrosis, angiogenesis, and lymphangiogenesis. Since the expression and function of LPA receptors are critical for cellular effects, selective antagonists may represent a potential treatment for a broad range of illnesses, such as cardiovascular diseases, idiopathic pulmonary fibrosis, voiding dysfunctions, and various types of cancers. More new LPA receptor antagonists have shown their therapeutic potentials, although most are still in the preclinical trial stage. This review provided integrative information and summarized preclinical findings and recent clinical trials of different LPA receptor antagonists in cancer progression and resistance. Targeting LPA receptors can have potential applications in clinical patients with various diseases, including cancer.
    關聯: CELLS-BASEL, v.10, n.7, 1629
    顯示於類別:[Dept. of Cosmetic Science and institute of cosmetic science] Periodical Articles

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    cells10071629.pdf1057KbAdobe PDF136檢視/開啟
    index.html0KbHTML574檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋